SMFR

(SPAC) Special Purpose Acquisition Investigation: SMFR, SFT, SKIL, SMRT, Contact Shareholder Rights Law Firm Johnson Fistel

Retrieved on: 
Sunday, January 15, 2023

SAN DIEGO, Jan. 14, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies ("SPACs"): Sema4 Holdings Corp. f/k/a CM Life Sciences, Inc. (NASDAQ: SMFR), Shift Technologies, Inc. f/k/a Insurance Acquisition Corporation (NASDAQ: SFT), Skillsoft Corp. f/k/a Churchill Capital Corporation II (NYSE: SKIL), and SmartRent, Inc. f/k/a Fifth Wall Acquisition Corp.

Key Points: 
  • SAN DIEGO, Jan. 14, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies ("SPACs"): Sema4 Holdings Corp. f/k/a CM Life Sciences, Inc. (NASDAQ: SMFR), Shift Technologies, Inc. f/k/a Insurance Acquisition Corporation (NASDAQ: SFT), Skillsoft Corp. f/k/a Churchill Capital Corporation II (NYSE: SKIL), and SmartRent, Inc. f/k/a Fifth Wall Acquisition Corp.
  • I (NYSE: SMRT).
  • If you are an investor who has suffered losses in connection with any of the SPACs purchased below: Click or paste the following web address into your browser to submit your losses:
    Shift Technologies, Inc. f/k/a Insurance Acquisition Corporation (NASDAQ: SFT): https://www.johnsonfistel.com/investigations/shift-technologies-inc-insu...
    Skillsoft Corp. f/k/a Churchill Capital Corporation II (NYSE: SKIL): https://www.johnsonfistel.com/investigations/skillsoft-corp-f-k-a-church...
    SmartRent, Inc. f/k/a Fifth Wall Acquisition Corp.
  • I (NYSE: SMRT): https://www.johnsonfistel.com/investigations/smartrent-inc-fifth-wall-ac...

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

Retrieved on: 
Monday, January 9, 2023

STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care.

Key Points: 
  • GeneDx now has the capability to combine the power of genomic insights with clinical data to improve health care for people and populations,” said Katherine Stueland, President and CEO of GeneDx.
  • Our preliminary results, which exceeded our outlook a year ago, validate our strategy to target higher growth areas of the genomics market,” said Kevin Feeley, Chief Financial Officer of GeneDx.
  • GeneDx will report its full financial results and other metrics during its fourth quarter and year-end 2022 conference call in early March.
  • GeneDx president and CEO, Katherine Stueland, will present at the J.P. Morgan Healthcare Conference on January 12 at 10:30 am PT.

Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Friday, December 30, 2022

STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.

Key Points: 
  • STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.
  • Katherine Stueland , President and Chief Executive Officer, will deliver a formal presentation on Thursday, January 12, 2023, at 10:30 a.m. PT.

New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

Retrieved on: 
Monday, December 5, 2022

The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it can lead to earlier diagnoses and more immediate potential changes in clinical management.

Key Points: 
  • The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it can lead to earlier diagnoses and more immediate potential changes in clinical management.
  • The research evaluates the incidence of mitochondrial disease caused by both nuclear DNA (nDNA) and mtDNA in 966 infants in the NICU who received both rapid exome sequencing and mtDNA sequencing and deletion testing concurrently.
  • Mitochondrial diseases are chronic, genetic disorders that occur when mitochondria fail to produce enough energy for the body to function properly.
  • Mitochondrial diseases are individually rare but, collectively, as this study shows, this group of disorders is not uncommon in clinical settings.

American Cancer Society Adds Four New Members to Its Board of Directors

Retrieved on: 
Monday, December 5, 2022

ATLANTA, Dec. 5, 2022 /PRNewswire/ -- The American Cancer Society (ACS) has named four new members to its board of directors, with all terms beginning on January 1, 2023.

Key Points: 
  • ATLANTA, Dec. 5, 2022 /PRNewswire/ -- The American Cancer Society (ACS) has named four new members to its board of directors, with all terms beginning onJanuary 1, 2023.
  • The ACS Board of Directors consists of 22 members, which includes five officers and 17 directors.
  • He has served on the American Cancer Society of Puerto Rico Board of Directors since 1990 including serving as president of the board.
  • "We are grateful to the outgoing American Cancer Society board members for their dedication and commitment to improving the lives of people with cancer and their families," said Michael Marquardt, 2022 Board Chair.

Sema4 Holdings Corp. Investors: November 7, 2022 Last Day to actively participate in the case. Please contact the Portnoy Law Firm to recover your losses

Retrieved on: 
Monday, November 7, 2022

Sema4 investors that purchased shares between March 14, 2022 and August 15, 2022 are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • Sema4 investors that purchased shares between March 14, 2022 and August 15, 2022 are encouraged to contact Lesley Portnoy, Esq.
  • Investors are encouraged to contact attorney Lesley F. Portnoy ,by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

Deadline Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders of Last Few Hours to Actively Participate

Retrieved on: 
Monday, November 7, 2022

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

Key Points: 
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
  • The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bed Bath & Beyond, Sema4, Medtronic, and Palantir and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, November 7, 2022

On March 25, 2022, Bed Bath & Beyond added three new directors appointed by Ryan Cohens investment firm, RC Ventures LLC.

Key Points: 
  • On March 25, 2022, Bed Bath & Beyond added three new directors appointed by Ryan Cohens investment firm, RC Ventures LLC.
  • Then, on August 18, 2022, Ryan Cohen, through his investment firm RC Ventures LLC, announced that he would sell his entire stake in Bed Bath & Beyond.
  • On August 19, 2022, Bed Bath & Beyond stock plunged to a new low of $9.68, dropping another 52.6% from the previous day.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

Retrieved on: 
Friday, November 4, 2022

STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022.

Key Points: 
  • STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022.
  • On the same day, Katherine Stueland , Chief Executive Officer of Sema4, and Kevin Feeley , Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time.
  • Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time.
  • Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

Sema4 Class Action Deadline Alert: Johnson Fistel, Globally-Recognized Law Firm Encourages Shareholders to Submit Their SMFR Losses

Retrieved on: 
Friday, November 4, 2022

SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Sema4 Holdings Corp. (Sema4 or the Company) (NASDAQ: SMFR , SMFRW ).

Key Points: 
  • SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Sema4 Holdings Corp. (Sema4 or the Company) (NASDAQ: SMFR , SMFRW ).
  • The class action is on behalf of shareholders who purchased Sema4 securities between March 14, 2022 and August 15, 2022, both dates inclusive (the Class Period).
  • An investor's ability to share any potential future recovery of the Sema4 class action lawsuit is not dependent upon serving as lead plaintiff.
  • Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia.